Emergent bulks up on BARDA

HHS's Biomedical Advanced Research and Development Authority awarded Emergent BioSolutions Inc. (NYSE:EBS) a contract worth up to $186.6 million to develop a recombinant protective antigen (rPA) anthrax vaccine. The contract comprises a two-year period valued at $51 million, with three option years that could increase the total contract value up to $186.6 million. Emergent's vaccine candidate is in Phase II testing. ...